Article Sidebar

Submitted
6 August 2020
Accepted
6 August 2020
Published
30 June 2020
Download
PDF
Statistic
Read Counter : 807 Download : 682

Main Article Content

Abstract

The limitation of echocardiography to measure chemotherapy cardiotoxicity at left locally advanced breast cancer with large ulcer is still serious problem. HsTnI and erCRP are biomarkers to detect cardiotoxicity that are cheap, easy to examine and available at Dr.Soetomo Hospital Surabaya. This study was to compare HsTnI, erCRP and echocardiography as cardiotoxicity predictors in locally advanced breast cancer with neoadjuvant CAF therapy. This study used one group pretest and posttest design among 23 locally advanced breast cancer patients. All patients underwent echocardiography, HsTnI, and erCRP examinations before and after 3 times chemotherapy and compared. The average age was 49.78±8.7. Statistically significant decrease in LVEF was found after treatment (67.98%±4.06 and 64.07%±3.53, p=0.000). HsTnI was significantly increased after treatment (0.007 µg/mL±0.004 and 0.043 µg/mL±0.051 p=0.000). erCRP was significantly decreased after treatment (1.043mg/dL±0.913 and 0.573mg/dL±0.444 p=0.044). Decreased LVEF and increased HsTnI was compared by its cardiotoxic cut-off. HsTnI was significantly better and faster to detect cardiotoxicity (0.033±0.051 p=0.002). In conclusion, strong correlation is present in the detection of cardiotoxicity between HsTnI and LVEF. HsTnI is faster than echocardiography, and could be alternative diagnostic to detect early cardiotoxicity.

Keywords

Locally advanced breast cancer doxorubicin cardiotoxicity LVEF echocardiography erCRP HsTnI

Article Details

License

Copyright (c) 2020 Folia Medica Indonesiana

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

  • Folia Medica Indonesiana is a scientific peer-reviewed article which freely available to be accessed, downloaded, and used for research purposes. Folia Medica Indonesiana (p-ISSN: 2541-1012; e-ISSN: 2528-2018) is licensed under a Creative Commons Attribution 4.0 International License. Manuscripts submitted to Folia Medica Indonesiana are published under the terms of the Creative Commons License. The terms of the license are:

    Attribution ” You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.

    NonCommercial ” You may not use the material for commercial purposes.

    ShareAlike ” If you remix, transform, or build upon the material, you must distribute your contributions under the same license as the original.

    No additional restrictions ” You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

    You  are free to :

    Share ” copy and redistribute the material in any medium or format.

    Adapt ” remix, transform, and build upon the material.

How to Cite
Hidayat, Y. H., Ishardyanto, H., & Anniwati, L. (2020). High Sensitive Troponin I and Extended Range C-Reactive Protein as Markers to Predict Cardiotoxicity in Locally Advanced Breast Cancer with Neoadjuvant CAF (Cyclophoshpamide, Adriamycin/Doxorubicin, 5Fluorouracil) Therapy. Folia Medica Indonesiana, 56(2), 91–98. https://doi.org/10.20473/fmi.v56i2.21205
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX

References

  1. Bovelli D, Plataniotis G, Roila F (2010). Cardiotoxicity of chemotherapeutic agents and radiotherapy-related heart disease: ESMO Clinical Practice Guidelines. Annals of Oncology 21, 277-282
  2. Feola M, Garrone O, Occelli M, Francini A, Biggi A, Visconti G, et al (2011). Cardiotoxicity after anthracycline chemotherapy in breast carcinoma: effects on left ventricular ejection fraction, troponin I and brain natriuretic peptide. Int J Cardiol 148, 194-810. DOI: 1016/j.ijcard.2009.09.564
  3. Garrone O, Crosetto N, Lo Nigro C, Catzeddu T, Vivenza D, Monteverde M, et al (2012). Prediction of anthracycline cardiotoxicity after chemotherapy by biomarkers kinetic analysis. Cardiovasc Toxicol 12, 135–4210. DOI: 1007/s12012-011-9149-4
  4. Ky B (2014). Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes and tratuzumab. Journal of the American College of Cardiology 63, 809-816
  5. Limat S, Demesmay K, Voillat L, Bernard Y, Deconinck E, Brion A (2003). Early cardiotoxicity of the CHOP regimen in aggressive non-Hodgkin's lymphoma. Annals of Oncology 14, 277-281
  6. Lisi DD, Leggio G, Vitale G, Arrotti S, Iacona R, Inciardi RM, Nobile D, Bonura F, Novo G, Russo A, Novo S (2014). Chemotherapy cardiotoxicity: cardioprotective drugs and early identification of cardiac dysfunction. J Cardiovasc Med 16, 1-5
  7. Onitilo AA, Engel JM, Liang H, et al (2012). High-sensitive C-reactive protein (Hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicity in HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat 134, 291-298
  8. Pizzino F, Vizzari G, Bomzer CA, Qamar R, Carerj S, Zito C, Khandheria BK (2014). Diagnosis of chemotherapy-induced cardiotoxicity. Journal of Patient-Centered Research and Reviews 1, 120-127
  9. Plana JC, Barac A, Ewer MS, Ky B, Scherrer-Crosbie M, Ganame J, Sebag IA, Agler DA, Badano LP, Banchs J, Cardinale D, Carver J, Cerqueira M, Decara JM, Edvardsen T, Flamm SD, Force T, Griffin BP, Jerusalem G, Liu JE, Magalhaes A, Marwick T, Sanchez LY, Sicari R, Villarraga HR, Lancellotti P (2014). Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. European Heart Journal - Cardiovascular Imaging 15, 1063-1093
  10. Pusat Data dan Informasi Kementerian Kesehatan Indonesia. Data Epidemiologi Kanker Indonesia. 2015. Available at http://www.depkes.go.id/resources/ download/pusdatin/infodatin/infodatin-kanker.pdf. Accessed October 19, 2016
  11. Reagan, Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M (2008). Biochemical markers for prediction of chemotherapy-induced cardiotoxicity. Am J Clin Pathol 130, 688-695
  12. Sawaya H (2012). American Heart Association: Assesment of echocardiography and viomarkers for the extended prediction in patients treated with antracyclines, taxanes, and trastuzumab. Boston, USA
  13. Shaikh AS, Saleem AF, Mohsin SS, Alam MM, Ahmed MA (2013). Anthracycline-induced cardiotoxicity: prospective cohort study from Pakistan. BMJ Open 3, 1-6
  14. Suyatno, Pasaribu ET (2010). Bedah onkologi diagnostik dan terapi 1st Ed. Jakarta, Sagung Seto
  15. Torres VM, Simic VD (2012). Doxorubicin-induced oxidative injury of cardiomyocytes – Do we have right strategies for prevention? In: Fiuza M (ed). Cardiotoxicity of Oncologic Treatment. Croatia, InTech, p 277-282
  16. Vetto JT, Luoh SH, Naik A (2009). Breast cancer in premenoupausal women Curr Probl Surg 46, 944-1004